Related Experiment Videos
Proglumide, a cholecystokinin receptor antagonist, reduces neuroleptic action in Huntington's chorea
R Piolti1, I Appollonio, M Perego
1Chair of Neurology, School of Medicine, University of Milan, Italy.
Insights
Proglumide, a cholecystokinin receptor antagonist, reduced haloperidol effectiveness in Huntington's chorea patients. Proglumide alone did not alter chorea severity, suggesting CCK modulates neurotransmitter systems involved in Huntington's disease.
Area of Science:
- Neuroscience
- Pharmacology
- Neurology
Background:
- Huntington's chorea is a neurodegenerative disorder characterized by involuntary movements (chorea).
- Haloperidol is a dopamine antagonist used for managing chronic symptoms.
- Cholecystokinin (CCK) is a neuropeptide implicated in various brain functions, including motor control.
Purpose of the Study:
- To investigate the effect of proglumide, a CCK receptor antagonist, on haloperidol treatment in Huntington's chorea patients.
- To assess the impact of proglumide alone on chorea severity.
Main Methods:
- A pilot study involving 8 patients with Huntington's chorea.
- Patients were on long-term haloperidol treatment.
- Proglumide was administered concomitantly with haloperidol and also alone.
Main Results:
- Concomitant administration of proglumide reduced the effectiveness of haloperidol in managing chronic chorea symptoms.
- Proglumide administered alone did not significantly alter chorea severity compared to placebo.
- These findings suggest proglumide interferes with haloperidol's therapeutic action.
Conclusions:
- CCK receptor antagonism may interfere with the efficacy of dopamine antagonists like haloperidol in Huntington's chorea.
- CCK may play a modulatory role in both dopaminergic and GABAergic systems relevant to chorea.
- Further research is warranted to elucidate the complex role of CCK in Huntington's chorea pathophysiology and treatment.
Abstract:
In a pilot study, proglumide, a cholecystokinin receptor antagonist, was administered to 8 patients affected from Huntington's chorea under long-term haloperidol treatment. The effectiveness of haloperidol on chronic symptomatology was reduced by the concomitant administration of proglumide; the latter drug, when administered alone, did not modify the severity of chorea compared to placebo. Possible explanations of these results are discussed, stressing the modulatory role of CCK not only on the dopaminergic, but also on the GABAergic system.